Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) in Q4 CY2024, with sales up 44.7% year on year to $13.53 billion. The company’s full-year revenue guidance of $59.5 billion at the midpoint ...

The upcoming report from Eli Lilly (LLY) is expected to reveal quarterly earnings of $2.46 per share, indicating an increase of 17.7% compared to the year-ago period. Analysts forecast revenues of ...

Eli Lilly's (LLY) Q4 earnings and sales beat estimates. Shares rise in pre-market trading.

JPMorgan analyst Chris Schott says Eli Lilly’s (LLY) Q4 miss represents a buying opportunity as the company is positioned for strong growth in 2025. The company’s 2025 sales guidance ...

Despite the big rally in LLY stock, analysts forecast more gains ahead. The median price target on the company’s shares is currently $600, 12% higher than the current trading price. Pfizer (PFE) ...

Investors anticipate updates on Eli Lilly's (LLY) weight loss therapy Zepbound and experimental Alzheimer's drug in its Q4 2023 earnings report. Read more here.

Eli Lilly and Company (NYSE:LLY) Q4 2022 Earnings Conference Call February 2, 2023 10:00 AM ETCompany Participants. Joe Fletcher - Senior Vice President of Investor Relations Dave Ricks - Chairman ...

Our Take on LLY’s Q4 Results. Lilly’s fourth-quarter results were rather uneventful, with the company already announcing preliminary sales numbers and 2025 sales outlook last month.

The upcoming report from Eli Lilly (LLY) is expected to reveal quarterly earnings of $2.46 per share, indicating an increase of 17.7% compared to the year-ago period.